Nasal carriage of CTX-M-55-producing Escherichia coli ST8369 in a healthy cohort in the city of Yangzhou, China.

This study aimed to investigate the prevalence and diversity of extended-spectrum β-lactamases (ESBL)-producing Escherichia coli isolates from healthy individuals in a community and to elucidate their dissemination mechanism. Cefotaxime-resistant E. coli were isolated from 95 samples of healthy persons from one community in Yangzhou, China, and were tested for minimal inhibitory concentrations of 14 antimicrobial agents. The isolates were subjected to whole genome sequencing by Illumina Hiseq or PacBio single-molecule real-time sequencing. A total of 30 cefotaxime-resistant E. coli isolates were obtained, carrying bla CTX-M (n=29) or bla DHA (n=1), of which the bla CTX-M-55 (n=19) was the most predominant genotype. One novel bla CTX-M variant bla CTX-M-252 was identified. Thirteen CTX-M-55-producing E. coli isolates belonged to ST8369 from nasal (n=12) or faecal (n=1) samples shared the identical cgMLST type, resistance profiles, resistance genes, plasmid replicons, and a 5,053-bp bla CTX-M-55 structure ΔIS26-ΔISEcp1-bla CTX-M-55-Δorf477-ΔTn2. The bla CTX-M-55 gene was located on IncHI2/ST3 plasmid in E. coli ST8369. The lengths of bla CTX-M/bla DHA-carrying contigs in the remaining 17 E. coli strains ranged from 1,663 to 382,836 bp, located on chromosome (n=4) or plasmids (n=5); the location of the other eight contigs could not be determined due to incomplete assembly. The bla CTX-M was associated with ISEcp1 as previously reported. Nasal colonization of CTX-M-55-producing ST8369 E. coli strains has occurred among healthy individuals in one community. There is a potential risk of antimicrobial resistance dissemination between humans within one community through close contact or environment via aerosols or dust. Therefore, surveillance of nasal carriage of bla CTX-M in communities is warranted to further monitor the spread of the antimicrobial resistance genes in China.

Introduction

Extended-spectrum cephalosporins are widely used in human clinics and veterinary medicine to treat infections caused by multidrug-resistant Gram-negative bacteria; thus, extended-spectrum β-lactamases (ESBL), particularly CTX-M enzymes, have been increasingly reported in human clinical settings and animals worldwide (Bevan et al., 2017). Globally, incidence of CTX-M ESBLs is increasing, bla CTX-M-15 and bla CTX-M-14 are the predominant genotypes detected in many parts of the world (Woerther et al., 2013; Bevan et al., 2017). The global dissemination of bla CTX-M is mainly due to the rapid horizontal transfer mediated by conjugative plasmids; the epidemic plasmids such as IncF, IncI, and IncHI2 facilitate the global spread of bla CTX-M in Enterobacteriaceae from humans, animals and the environment, particularly in Escherichia coli (Bevan et al., 2017; Rozwandowicz et al., 2018; Partridge et al., 2018). Mobile elements such as ISEcp1, IS26, and ISCR1 have also played an essential role in the blaCTX-M transmission (Bevan et al., 2017; Partridge et al., 2018). In addition, some successful E. coli clones, such as the E. coli clone ST131 lineage diffused worldwide, are also responsible for bla CTX-M-15 global dissemination, mostly in human clinics (Bevan et al., 2017).

To date, many studies have focused on CTX-M-producing Enterobacteriaceae from clinical patients. However, the high prevalence of CTX-M-producing E. coli colonizing the intestinal tract of healthy persons in communities is of particular concern, since they could be a major reservoir of bla CTX-M (Woerther et al., 2013; Bevan et al., 2017; Chen et al., 2021). In this study, we aimed to investigate the prevalence and characterization of extended-spectrum β-lactamases (ESBL)-producing E. coli isolates from healthy individuals in a community from Yangzhou, China, to elucidate their dissemination mechanism within this small-scale community.

Materials and methods

Sample collection and antimicrobial susceptibility testing

From April 9th to May 17th 2021, 58 fecal samples and 37 nasal swabs of 72 healthy volunteers (3 male and 69 female) with no obvious disease symptoms at the age of 15-46 were collected from 37 apartments located in three buildings in one community in Yangzhou, China. Participants had been exposed to antimicrobial agents in the three months prior to sample collection were excluded from this study. This small-scale community with approximately 2000 individuals located in the urban area of Yangzhou, and included three main areas, and one building was randomly selected to sample in each area ( ). Individual written informed consent for samples was obtained from all volunteers. Samples were incubated in LB broth (OXOID, Basingstoke, UK) for 18~24 h and then cultured on the MacConkey agar (Haibo, Qingdao, China) with 2 mg/L cefotaxime. One E. coli isolate per plate was selected and identified by 16S rRNA gene sequencing using PCR and Sanger sequencing (Kim et al., 2010). The cefotaxime-resistant E. coli isolates were tested susceptibility to 14 antimicrobial agents including ampicillin, cefotaxime, meropenem, gentamicin, amikacin, streptomycin, tetracycline, chloramphenicol, florfenicol, nalidixic acid, ciprofloxacin, colistin, fosfomycin, and sulfamethoxazole/trimethoprim by using the agar dilution or broth microdilution method (limited to colistin). The results were interpreted according to Clinical Laboratory Standards Institute (CLSI) M100, 30th edition (CLSI, 2020). E. coli ATCC 25922 was used as the quality control strain.

Whole genome sequencing and analysis

All cefotaxime-resistant E. coli isolates were sequenced by Illumina Hiseq. The library was constructed using NEB NEXT Ultra DNA Library Prep Kit for Illumina (New England Biolabs, USA) and 150 bp paired-end reads were obtained. For each E. coli isolate performed WGS, at least 100-fold coverage of raw reads was collected. The 150 bp pair-end raw reads were trimmed and filtered by the NGSQC toolkit 2.3.3, then were assembled into contigs using SPAdes 3.8.2 (Bankevich et al., 2012). One representative ST8369 E. coli isolate YZ21HCE18 was sequenced using PacBio single-molecule real-time sequencing. The phylogenetic groups of E. coli were confirmed according to previously described protocol by using assembled contigs (Clermont et al., 2000). The genomes were subjected to analysis of multilocus sequence typing (MLST), core genome multilocus sequencing typing (cgMLST), resistance genes, mutations and plasmids by using the Center for Genomic Epidemiology (CGE) pipelines (http://www.genomicepidemiology/org/). The phylogenetic tree of these isolates was constructed using Parsnp (https://harvest.readthedocs.io/en/latest/content/parsnp.html) and visualized by iTOL (Letunic and Bork, 2016). The bla CTX-M/ bla DHA-carrying contigs were retrieved from the draft genomes and analyzed by ISfinder (https://www-is.biotoul.fr/) and BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi). The bla CTX-M-bearing plasmid pYUYZ18-1 in strain YZ21HCE18 was compared with other ST8369 E. coli isolates using BRIG.

Conjugation assay

The transferability of cefotaxime resistance was determined using conjugation experiments as previously described (Chen et al., 2007) and streptomycin-resistant E. coli C600 as the recipient. Transconjugants were selected using 2 mg/L cefotaxime and 3,000 mg/L streptomycin, and were confirmed by detecting bla CTX-M or bla DHA-1 using PCR and sequencing (Chen et al., 2004; Liu et al., 2007).

Results

Prevalence and genotype distribution of cefotaxime-resistant E. coli

Thirty cefotaxime-resistant E. coli isolates were obtained from 12 nasal swabs and 18 fecal samples from 27 individuals ( ). The bla CTX-M-55 (n=19) gene was identified as the most predominant genotype, followed by bla CTX-M-14 (n=5), bla CTX-M-65 (n=2), bla CTX-M-15 (n=1), bla CTX-M-64 (n=1), and bla DHA-1 (n=1) ( ). One novel bla CTX-M variant bla CTX-M-252 (GenBank accession no. OL884447) was identified, and differed from bla CTX-M-65 by a single nucleotide resulting in one amino acid change (A32V).

Table 1

Chracterization of cefotaxime-resistant Escherichia coli isolates in this study.

Strainsa	Sourceb	Sampling Date	MLST	Phylogenetic group	ESBL genotype	Antimicrobial susceptibility profilec	Plasmid	Mutationsd	Length of bla CTX/DHA-contig (bp)
YZ21HCE7*	nasal swab, F	2021/5/14	8369	B1	bla CTX-M-55	AMP/CTX/GEN/STR/TET/CHL/FFC/SXT	IncHI2, F102:A17:B-	N	5,053
YZ21HCE8*	nasal swab, F	2021/5/14	8369	B1	bla CTX-M-55	AMP/CTX/GEN/STR/TET/CHL/FFC/SXT	IncHI2, F102:A17:B-	N	5,053
YZ21HCE9*	nasal swab, F	2021/5/14	8369	B1	bla CTX-M-55	AMP/CTX/GEN/STR/TET/CHL/FFC/SXT	IncHI2, F102:A17:B-	N	5,053
YZ21HCE18*	nasal swab, F	2021/5/14	8369	B1	bla CTX-M-55	AMP/CTX/GEN/STR/TET/CHL/FFC/SXT	IncHI2, F102:A17:B-	N	5,053
YZ21HCE19*	nasal swab, F	2021/5/14	8369	B1	bla CTX-M-55	AMP/CTX/GEN/STR/TET/CHL/FFC/SXT	IncHI2, F102:A17:B-	N	5,053
YZ21HCE21*	nasal swab, F	2021/5/16	8369	B1	bla CTX-M-55	AMP/CTX/GEN/STR/TET/CHL/FFC/SXT	IncHI2, F102:A17:B-	N	5,053
YZ21HCE22*	nasal swab, F	2021/5/16	8369	B1	bla CTX-M-55	AMP/CTX/GEN/STR/TET/CHL/FFC/SXT	IncHI2, F102:A17:B-	N	5,053
YZ21HCE26*	feces, F	2021/5/16	8369	B1	bla CTX-M-55	AMP/CTX/GEN/STR/TET/CHL/FFC/SXT	IncHI2, F102:A17:B-	N	5,053
YZ21HCE27*	nasal swab, F	2021/5/17	8369	B1	bla CTX-M-55	AMP/CTX/GEN/STR/TET/CHL/FFC/SXT	IncHI2, F102:A17:B-	N	5,053
YZ21HCE28*	nasal swab, F	2021/5/17	8369	B1	bla CTX-M-55	AMP/CTX/GEN/STR/TET/CHL/FFC/SXT	IncHI2, F102:A17:B-	N	5,053
YZ21HCE29*	nasal swab,M	2021/5/17	8369	B1	bla CTX-M-55	AMP/CTX/GEN/STR/TET/CHL/FFC/SXT	IncHI2, F102:A17:B-	N	5,053
YZ21HCE30*	nasal swab,M	2021/5/17	8369	B1	bla CTX-M-55	AMP/CTX/GEN/STR/TET/CHL/FFC/SXT	IncHI2, F102:A17:B-	N	5,053
YZ21HCE31*	nasal swab, F	2021/5/17	8369	B1	bla CTX-M-55	AMP/CTX/GEN/STR/TET/CHL/FFC/SXT	IncHI2, F102:A17:B-	N	5,053
YZ21HCE1*	feces, F	2021/4/9	773	A	bla CTX-M-14	AMP/CTX/NAL/CIP/FOS	F2:A-:B10, IncX1, Col(BS512)	gyrA(S83L+D87N), parC (S80I), parE (S458A)	1,687
YZ21HCE2*	feces, F	2021/4/9	453	B1	bla DHA-1	AMP/CTX/STR/TET/NAL	IncHI2, IncFII, IncFIB	N	18,905
YZ21HCE3*	feces, F	2021/4/9	5614	B1	bla CTX-M-15	AMP/CTX/STR/SXT	IncK	N	35,054
YZ21HCE4	feces, F	2021/4/10	1434	A	bla CTX-M-14	AMP/CTX/NAL	IncY, IncX1, IncFIB(K), Col156, IncFII(pCRY)	N	21,609
YZ21HCE5	feces, F	2021/4/10	95	B2	bla CTX-M-65	AMP/CTX/GEN/STR/TET/CHL/FFC/NAL/SXT	IncHI2, F18:A-:B1:C4	gyrA (S83L)	3,019
YZ21HCE6*	feces, F	2021/4/10	10	C	bla CTX-M-55	AMP/CTX/TET	IncI1, F18:A-:B1:C4	N	21,977
YZ21HCE10*	feces, F	2021/5/14	12741	B1	bla CTX-M-252	AMP/CTX/GEN/CHL/FFC/NAL/CIP/CL/SXT	IncI1, IncI2, IncY, F18:A-:B1:C4	gyrA(S83L+D87N), parC (S80I), parE (S458A)	1,663
YZ21HCE12	feces, F	2021/5/14	4373	F	bla CTX-M-64	AMP/CTX/GEN/STR/TET/CHL/FFC/FOS/SXT	F18:A-:B1:C4, ColpVC	N	160,049
YZ21HCE13	feces, F	2021/5/15	457	F	bla CTX-M-55	AMP/CTX/GEN/NAL/CIP	F18:A-:B1:C4	gyrA(S83L+D87Y), parC (S80I+E84G), parE (I355T)	382,836
YZ21HCE14*	feces, F	2021/5/15	1049	B1	bla CTX-M-14	AMP/CTX/GEN/TET/CHL/FFC	IncK, F18:A-:B1:C4	N	96,577
YZ21HCE15	feces, F	2021/5/14	115	E	bla CTX-M-55	AMP/CTX/STR/TET/CHL/FFC/NAL/SXT	F24:A-:B1, IncI1, IncX1, Col8282, Col156	gyrA (S83L), parE (I464F)	2,763
YZ21HCE16*	feces, F	2021/5/15	10	C	bla CTX-M-55	AMP/CTX/TET/CHL/FFC	IncX1, F46:A-:B24	N	46,033
YZ21HCE17	feces, F	2021/5/14	2614	B1	bla CTX-M-65	AMP/CTX/STR/TET/CHL/FFC/NAL/SXT	IncY, IncQ1	N	3,895
YZ21HCE20	feces, F	2021/5/16	12743	A	bla CTX-M-55	AMP/CTX/GEN/TET/CHL/FFC/NAL/SXT	IncFIB, IncY	N	38,904
YZ21HCE23*	feces, F	2021/5/16	49	B1	bla CTX-M-14	AMP/CTX/GEN/TET/CHL/FFC/SXT	F18:A-:B1:C4, IncK	N	65,116
YZ21HCE24*	feces, F	2021/5/16	442	B1	bla CTX-M-55	AMP/CTX/FOS	F16:A-:B-	N	2,763
YZ21HCE25	feces, F	2021/5/16	12744	B1	bla CTX-M-14	AMP/CTX/GEN/STR/TET/CHL/FFC/NAL/CIP/FOS/SXT	F55:A-:B6, p0111	gyrA(S83L+D87N), parC (S80I)	3,320

a, * indicates that strain could successfully transfer blaCTX-M/DHA to E. coli C600 by conjugation; Underline indicates nasal and fecal samples obtained from the same individual, YZ21HCE7 and YZ21HEC10, YZ21HCE15 and YZ21HCE18, YZ21HCE17 and YZ21HCE19; Boldface indicates individuals from the same apartment.

b, F, female; M, male.

c, AMP, ampicillin; CTX, cefotaxime; GEN, gentamicin; STR, streptomycin; TET, tetracycline; CHL, chloramphenicol; FFC, florfenicol; NAL, nalidixic acid; CIP, ciprofloxacin; CL, colistin; FOS, fosfomycin; SXT, sulfamethoxazole/trimethoprim; all strains were susceptible to meropenem and amikacin.

d, N, not found.

Characterization of cefotaxime-resistant E. coli isolates

All ESBL-producing isolates exhibited an MIC of 8 to >128 mg/L to cefotaxime, and also showed resistance to multiple antibiotics, but were susceptible to meropenem and amikacin ( ). Twenty-two of them successfully transfer cefotaxime resistance to E. coli C600 by conjugation ( ). In addition to bla CTX-M/bla DHA, they carried one to 18 resistance genes, such as bla TEM, tet(A), floR, qnrS1, fosA3, and mcr-1 ( ); mutations within gyrA (S83L, D87N/Y), parC (S80I), or parE (I355T, S458A) were observed in six of them ( ). Phylogenetic group analysis showed that group B1 was predominant (21; 70%), which was frequently associated with commensal or intestinal pathogenic strains (Clermont et al., 2000); followed by group A (3; 10%), group C (2; 6.67%), group F (2; 6.67%) and group E (1; 3.33%) ( ). Only one CTX-M-65-producing isolate belonged to extraintestinal virulent group B2.

Figure 1

The maximum likelihood tree of cefotaxime-resistant E. coli isolates in this study compared with E. coli ST8369 isolates from EnteroBase (https://enterobase.warwick.ac.uk/) (in blue) based on cgSNP analysis. Antibiotic resistance genes with >90% sequence homology and coverage are shown.

Thirty ESBL-producing isolates were assigned to 14 known STs and three novel STs (ST12741, ST12743 and ST12744) ( ). The most prevalent STs among them were ST8369 (n=13). So far, only nine ST8369 E. coli isolates were retrieved from EnteroBase (https://enterobase.warwick.ac.uk/) originating from humans, wild animals, and the environment ( ), and none of them carried resistance genes or mutations associated with quinolone resistance. To reveal the genetic differences between 22 E. coli ST8369 isolates, we analyzed their cgMLST profiles (cgSTs) based on 2513 alleles (Zhou et al., 2020). Among the identified seven cgSTs, cgST 75038 (n=14) was the dominant type shared by 13 strains in our study and one isolate PS00212 ( ). Thirteen E. coli ST8369 strains from nasal (n=12) or fecal (n=1) samples of different individuals in this study shared the same cgST, resistance profiles, resistance genes, and plasmid replicons ( and ), indicating that there is a reservoir of this lineage in the community.

The genetic structures of bla CTX-M/bla DHA in 30 ESBL-producing E. coli isolates

The lengths of bla CTX-M/bla DHA-carrying contigs ranged from 1,663 to 382,836 bp, located on chromosome (n=4) or plasmids (n=5). Twenty-one contigs were short (1,663 to 5,053 bp) due to incomplete assembly and the high number of insertion elements; they did not have replicon genes or plasmid backbone; thus, it is difficult to determine their location ( ; ).

Figure 2

The genetic environments of blaCTX-M/blaDHA in 30 E. coli isolates in this study. (A) blaCTX-M-55; (B) blaCTX-M-14; (C) blaCTX-M-65/-252; (D) blaCTX-M-64; (E) blaCTX-M-15; (F) blaDHA. The extents and directions of antibiotic resistance (red arrows) and other genes (black arrows) are indicated. The blue arrows indicate chromosomal genes. ISs are shown as boxes labeled with their name. Tall bars represent the inverted repeats (IR) of transposon. Δ indicates a truncated gene or mobile element. Arrows and sequences indicate direct repeats.

In YZ21HCE13, the 3,241-bp transposition unit (ISEcp1-bla CTX-M-55-Δorf477-ΔTn2) was inserted into the chromosome and generated 5-bp direct repeats (DRs) ( ). A similar insertion (ISEcp1-bla CTX-M-55-Δorf477) with a different location had occurred in the chromosome of YZ21HCE20. Similarly, a 3,050-bp segment (ISEcp1-bla CTX-M-55-Δorf477-ΔTn2) with DRs (5’-TAACA-3’) was inserted into the plasmid backbone in YZ21HCE6 ( ), this bla CTX-M-55-bearing contig (21,977 bp) was identical to those of F18:A-:B1:C4 plasmids, such as pTREC1 (E. coli, MN158989) ( ). In YZ21HCE16, the bla CTX-M-55-carrying contig was 46,033 bp in size and similar to IncX1 plasmids such as p40EC-5 (CP070925) and pPK8277-49kb (CP080137) ( ). bla CTX-M-55 was associated with the commonly observed structure ΔIS26-ΔISEcp1-bla CTX-M-55-Δorf477-ΔTn2, and three additional resistance genes aph(3’)-Ia, qnrS1 and tet(A) were co-located in this contig ( ). The 2,763-bp bla CTX-M-55 region in isolates YZ21HCE15 and YZ21HCE24 were identical, including the typical transposition unit (ΔISEcp1-bla CTX-M-55-orf477) and a truncated bla TEM-1b downstream, which was commonly observed in many bla CTX-M-55-carrying plasmids, e.g., pHNMC02 (MG197489). All ST8369 E. coli isolates (n=13) had identical 5,053-bp bla CTX-M-55-positive contigs with structure ΔIS26-ΔISEcp1-bla CTX-M-55-Δorf477-ΔTn2, except strain YZ21HCE29 (one nucleotide change). The complete sequence of YZ21HCE18 as representative ST8369 E. coli was obtained ( ). The bla CTX-M-55 gene was located on plasmid pYUYZ18-1 with a size of 248,665 bp, belonged to IncHI2/ST3 plasmid with a similar organization to other IncHI2 plasmids. In addition to bla CTX-M-55, pYUYZ18-1 contained numerous resistance genes, including aac(3)-IId, aph(3’)-Ia, strAB, tet(A), mph(A), qnrS1, floR, sul2, sul3, dfrA14, and arr-2. Similar pYUYZ18-1 plasmids were also present in other ST8369 E. coli strains in this study ( ).

Two bla CTX-M-14-positive contigs from isolates YZ21HCE14 and YZ21HCE23 displayed >99.9% similarity to IncK1 plasmids pD16EC0206-1 (E. coli, CP088610) and pJX1-2 (Klebsiella pneumoniae, CP064254) ( ). The 3,060-bp bla CTX-M-14 transposition unit (ISEcp1-bla CTX-M-14-ΔIS903) with 5-bp DRs (5’-GCGGA-3’) was inserted downstream of the plasmid conjugal transfer gene traK ( ). In isolates YZ21HCE1, YZ21HCE4, and YZ21HCE25, a similar bla CTX-M-14 transposition unit was observed, differed by deletions involving ISEcp1 and/or IS903. In YZ21HCE4, the 2,996-bp fragment (ISEcp1-bla CTX-M-14-ΔIS903) was embedded in a 21,609-bp contig associated with the chromosome of E. coli. The 1,972-bp fosA3 segment (fosA3-orf1-Δorf2-ΔIS26) was present downstream of IS903 in YZ21HCE25 ( ).

As observed in , the typical (ISEcp1-bla CTX-M-9G-IS903-iroN) transposition unit was found in isolates YZ21HCE5 (bla CTX-M-65), YZ21HCE17 (bla CTX-M-65), and YZ21HCE10 (bla CTX-M-252), although ISEcp1 was incomplete. In YZ21HCE17, the bla CTX-M-65 unit was inserted in an incomplete Tn1722. However, IS903 was truncated by IS26 at the 3’ end in YZ21HCE5, resulting in the deletions of iroN and 701 bp of IS903. Similarly, an incomplete IS903 (80-bp) was also observed in YZ21HCE10. A 1,205-bp structure consisting of two hypothetical proteins plus ΔIS26 (76-bp) was located upstream of bla CTX-M-65 transposition unit with a 64-bp spacer in YZ21HCE5. Remnants of this structure were also identified upstream of the bla CTX-M-65 unit in YZ21HCE17 (214 bp) and YZ21HCE10 (201 bp).

The bla CTX-M-64 was located on the chromosome of YZ21HCE12. The 160,049-bp bla CTX-M-64-carrying contig showed highly (>98.0%) similarity to the corresponding region of E. coli chromosome such as Z30 (CP066844) and LD67-1 (CP061185). Furthermore, a 3,045-bp region (ISEcp1-bla CTX-M-64-Δorf477-ΔTn2) in YZ21HCE12 was identical to those of chromosome of E. coli 3952 (MT773682) and plasmid pM-64-4467-1 (MT773679) from healthy humans in Hangzhou, China (Chen et al., 2021).

The bla CTX-M-15-positive contig (35,054 bp) in YZ21HCE3 was similar to IncI1 plasmid pBHBSTW-00321_3 (E. coli, CP056606) with 86% coverage and 98.36% identity ( ). The bla CTX-M-15 gene was associated with genetic content ΔTn2-ΔISEcp1-bla CTX-M-15-Δorf477-ΔTn2, seen in several plasmids, such as p5908-2 (Shigella flexneri, CP045523) and p92 (E. coli, CP041521). The bla CTX-M-15 resistance module was followed by a 5,752-bp structure qnrS1-ISKpn19-ΔIS26 ( ).

The bla DHA-carrying contig (18,905 bp) of YZ21HCE2 was identical to the corresponding regions of multiple plasmids such as pM2901 (Shigella sonnei, CP061363), except for the insertion of one Tn3 family transposon within pspC flanked by 5-bp DRs in YZ21HCE2. The core structure sul1-qacEΔ1-ampR-bla DHA-1-pspDCBAF-qnrB4 is commonly observed in numerous plasmids from various species (e.g., Salmonella, Klebsiella pneumoniae, Citrobacter freundii), highlighting the co-transfer ability of bla DHA-1 and qnrB4.

Discussion

The bla CTX-M gene has been globally disseminated in different sources, with bla CTX-M-14 and bla CTX-M-15 being dominant (Bevan et al., 2017). In this study, bla CTX-M-55 is the most predominant genotype in healthy individuals, which agrees with the increasing prevalence of bla CTX-M-55 in both animals and patients in China (Bevan et al., 2017). As a variant of bla CTX-M-15, bla CTX-M-55 was first reported in clinical E. coli and K. pneumoniae isolates in Thailand in 2007 (Kiratisin et al., 2007). Recently, bla CTX-M-55 has become the predominant CTX-M genotype in E. coli and Salmonella from food animals, food products, and patients in China (Rao et al., 2014; Zhang et al., 2014; Fu et al., 2020; Huang et al., 2020; Liu et al., 2022; Zeng et al., 2022). One novel bla CTX-M variant bla CTX-M-252 was identified in this study. CTX-M-252 and CTX-M-65 differ by a single amino acid and share a similar genetic structure, suggesting a common lineage. Further investigation of bla CTX-M-252 is needed.

In communities, faecal carriage rates of bla CTX-M are increasing, particularly in developing countries (Woerther et al., 2013; Bevan et al., 2017). However, investigation of bla CTX-M in nasal samples of healthy humans is rare. Previously, one (1/77, 1.30%) CTX-M-producing E. coli isolate was obtained from the nasal sample of a healthy human working at a pig abattoir in Cameroon (Founou et al., 2018). A high nasal carriage rate (32.43%) of bla CTX-M was observed in this study, and nasal colonization of ST8369 E. coli producing CTX-M-55 among healthy persons occurred in one community in Yangzhou, China. It suggests that nasal carriage of bla CTX-M is possibly common in humans. However, the small number of samples and communities is a limitation of this study. The acquisition of bla CTX-M-55 and other resistance genes by ST8369 is mediated by the horizontal transfer of IncHI2 plasmid, followed by clonal dissemination. E. coli ST8369 is rarely described worldwide and may represent an emerging clone in humans, animals, and the environment. Nasal colonization of bla CTX-M-55-carrying ST8369 E. coli suggests a potential risk of antimicrobial resistance dissemination between humans by the spread of clonal lineages in the small-scale community through close contact or environment via aerosols or dust. Therefore, the clinical importance of nasal carriage of CTX-M-producing E. coli might be underestimated. Although horizontal transfer is the main reason for bla CTX-M dissemination, clonal spread of bla CTX-M-harbouring strains, such as E. coli ST8369 in this study, CTX-M-15-producing E. coli ST949 in water surfaces, E. coli ST2179 encoding CTX-M-65 in retail meat, and bla CTX-M-55-carrying Salmonella Typhimurium ST34 in patients (Bevan et al., 2017; Falgenhauer et al., 2021; Leão et al., 2021; Zeng et al., 2022) is another important route for bla CTX-M transmission.

Horizontal transfer mediated by plasmids and mobile elements is responsible for the global spread of bla CTX-M (Bevan et al., 2017; Partridge et al., 2018). For example, IncI, IncFII, and IncHI2 plasmids facilitate the horizontal transmission of bla CTX-M in E. coli and Salmonella from various sources (Chen et al., 2021; Guo and Zhao, 2021; Yang et al., 2014; Nadimpalli et al., 2019; Zhang et al., 2021; Zeng et al., 2021). In this study, various plasmids such as IncHI2, IncK1, IncX1, and IncI1 were associated with bla CTX-M. Although we were not able to determine the location of bla CTX-M in some E. coli isolates in this study due to incomplete assembly, sequence analysis indicates that ISEcp1 plays an important role in bla CTX-M dissemination among E. coli isolates and facilitates the horizontal transfer of bla CTX-M from plasmids to chromosomes in distinct integration sites. The chromosomal integration of bla CTX-M is increasingly reported in E. coli, K. pneumoniae, Salmonella, Proteus mirabilis and some other species of Enterobacteriaceae with the help of mobile elements (Huang et al., 2017; He et al., 2017; Zeng et al., 2022; Yoon et al., 2022). Chromosomal integration of bla CTX-M seems to be an adaptive evolution in response to antimicrobial pressure (Yoon et al., 2022).

In conclusion, we report nasal colonization of CTX-M-55-producing E. coli ST8369 associated with IncHI2 plasmid in healthy individuals in one community from Yangzhou, China. Therefore, continued surveillance of nasal carriage of bla CTX-M in communities is warranted.

Accession Numbers

The sequences have been deposited in the GenBank under accession number: PRJNA819533.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/ .

Ethics statement

The studies involving human participants were reviewed and approved by Yangzhou University. The participants provided their written informed consent to participate in this study.

Author contributions

JW and Q-CL conceived and designed the experiments, Z-YW, YJ, Y-QS, H-FL, and M-JL carried out the experiments. Z-YW and JW analyzed the data and wrote the manuscript. Q-CL and XJ revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the National Natural Science Foundation of China (no. 31902319), the fifth phase of the “333 project” scientific research project in Jiangsu Province (no. BRA2020002), and Postgraduate Research &Practice Innovation Program of Jiangsu Province (Yangzhou University) (no. KYCX22_3536).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.